Development of trofinetide for the treatment of Rett syndrome: from bench to bedside
Frontiers in Pharmacology · 22.01.2024 · 14
DOI: 10.3389/fphar.2023.1341746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 22.01.2024. Verfasst von Melissa Kennedy und 11 weiteren Autor:innen. Beteiligte Einrichtung: International Rett Syndrome Foundation, Cincinnati, OH, United States. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Rett syndrome (RTT) is rare neurodevelopmental disorder caused by mutations in the MECP2 gene that encodes methyl-CpG-binding protein 2 (MeCP2), a DNA-binding protein with roles in epigenetic regulation of gene expression. Functional loss of MeCP2 results in abnormal neuronal maturation and plasticity, characterized by loss of verbal communication and loss of fine and gross motor function, among others. Trofinetide, a synthetic analog of glycine-proline-glutamate, was approved by the US Food and Drug Administration for the treatment of RTT in adult and pediatric patients aged 2 years and older. Here, we present the development of trofinetide from bench research to clinical studies and emphasize how the collaboration between academia, the pharmaceutical industry, and patient advocacy led to the recent approval. The bench-to-bedside development of trofinetide underscores the value of collaboration between these groups in the development and approval of treatments for rare diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- International Rett Syndrome Foundation, Cincinnati, OH, United States.
- Neuren Pharmaceuticals Ltd., Melbourne, VIC, Australia.
- Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States.
- Division of Pediatric Neurology, University of Alabama at Birmingham, Birmingham, AL, United States.
- Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, United States.
- Institute of Neuroscience, Trinity College, Dublin, Ireland.
Förderung
- NICHD NIH HHS
Zitieren
APA
Kennedy, M., Glass, L., Glaze, D. G., Kaminsky, S., Percy, A. K., Neul, J. L., Jones, N. E., Tropea, D., Horrigan, J. P., Nues, P., Bishop, K. M., & Youakim, J. M. (2024). Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1341746
Vancouver
Kennedy M, Glass L, Glaze DG, Kaminsky S, Percy AK, Neul JL, et al. Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. Frontiers in Pharmacology. 2024;14. doi:10.3389/fphar.2023.1341746
BibTeX
@article{Kennedy2024,
author = {Kennedy, Melissa and Glass, Larry and Glaze, Daniel G and Kaminsky, Steve and Percy, Alan K and Neul, Jeffrey L and Jones, Nancy E and Tropea, Daniela and Horrigan, Joseph P and Nues, Paige and Bishop, Kathie M and Youakim, James M},
title = {Development of trofinetide for the treatment of Rett syndrome: from bench to bedside},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {14},
doi = {10.3389/fphar.2023.1341746}
}
EUVIMED